Format

Send to

Choose Destination
Vaccine. 2009 Jun 24;27 Suppl 2:B30-41. doi: 10.1016/j.vaccine.2009.05.003. Epub 2009 May 27.

Quadrivalent meningococcal conjugate vaccines.

Author information

1
Department of Paediatrics, Mater Dei Hospital, Tal-Qroqq, Msida, MSD 2090, Malta. dpace@mail.global.net.mt

Abstract

Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.

PMID:
19477560
DOI:
10.1016/j.vaccine.2009.05.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center